A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 272 participants.

Also called NCT06256549

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 272 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06256549
Other papers using this trial's data
  • Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial Annals of internal medicine, 2026-08 DOI, PubMed 42372276

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06256549. Randomized; no masking; primary purpose treatment. Start 2023-08-09 (actual); primary completion 2024-07-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
Intervention (Drug)
GZR18
Intervention (Drug)
Semaglutide
Lead sponsor
Gan and Lee Pharmaceuticals, USA (class: industry)

Record details

Record id
cardio:ct-nct06256549
Content hash
4ccfa9b40f05b2d3875b37a5599541e50e5a5180f1a584fafc0388a64aafffc3